Raymond James Downgrades Acadia Pharmaceuticals (ACAD) to Outperform

March 9, 2021 5:10 AM EST
Get Alerts ACAD Hot Sheet
Price: $21.15 -0.24%

Rating Summary:
    10 Buy, 13 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Raymond James analyst Danielle Brill downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Strong Buy to Outperform with a price target of $35.00 (from $65.00).

The analyst comments "We are downgrading ACAD from Strong Buy to Outperform following today’s disclosure that the FDA found deficiencies in their sNDA filing that preclude labeling discussions for Nuplazid in dementia related psychosis (DRP). We have no good guesses as to what “deficiencies” the FDA found, but one thing is quite clear – the regulatory outlook for DRP suddenly appears quite dire. We believe ACAD management was as transparent as possible in tonight’s update, but given the lack of feedback from the agency to their multiple inquiries (since being notified on March 3), it unfortunately looks like a CRL is now the most likely outcome for Nuplazid by its April 3 PDUFA date. Considering Nuplazid was granted breakthrough therapy designation (BTD), and nothing major was ever discussed/ highlighted by the agency in prior interactions throughout the review process, we remain hopeful that the deficiencies are minor and will only result in an approval delay. Still, it is possible that the deficiency is something more substantial (requiring another study)."

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $29.40 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Raymond James, PDUFA, FDA